Cost-effective approaches to influenza prevention and treatment

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 5, Issue 2, 2005, Pages 141-152

  Rothberg, Michael B ^a  

^a BAYSTATE MEDICAL CENTER   (United States)

Author keywords

Antiviral therapy; Cost effectiveness; Economic analysis; Influenza; Review; Vaccination

Indexed keywords

AMANTADINE; AMANTADINE DERIVATIVE; ANTIVIRUS AGENT; INFLUENZA VACCINE; LIVE VACCINE; OSELTAMIVIR; RIMANTADINE; SIALIDASE INHIBITOR; ZANAMIVIR;

CLINICAL PRACTICE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; DRUG COST; DRUG DOSE REGIMEN; ECONOMIC EVALUATION; FLU LIKE SYNDROME; GUILLAIN BARRE SYNDROME; HEALTH SURVEY; HUMAN; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INFLUENZA VIRUS B; INJECTION PAIN; NOSE CONGESTION; REVIEW; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SORE THROAT; TREATMENT INDICATION;

EID: 17544382909     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.5.2.141     Document Type: Review

References (80)

1. Szucs T. The socio-economic burden of influenza. J. Antimicrob. Chemother. 44(Suppl. B), 11-15 (1999).
2. Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 53, 1-40 (2004).
3. Deaths and percentage of total deaths for the 10 leading causes of death. National Vital Statistics Reports, USA. 52, 9 (2003).
4. Reichert TA, Sugaya N, Fedson DS, Glezen WP, Simonsen L, Tashiro M. The Japanese experience with vaccinating schoolchildren against influenza. N. Engl. J. Med. 344, 889-896 (2001).
5. Nichol KL, Margolis KL, Lind A et al. Side effects associated with influenza vaccination in healthy working adults. A randomized, placebo-controlled trial. Arch. Intern. Med. 156, 1546-1550 (1996).
6. Allsup SJ, Gosney M, Regan M, Haycox A, Fear S, Johnstone FC. Side effects of influenza vaccination in healthy older people: a randomised single-blind placebo-controlled trial. Gerontology 47, 311-314 (2001).
7. Lasky T, Terracciano GJ, Magder L et al. The Guillain-Barre syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N. Engl. J. Med. 339, 1797-1802 (1998).
8. Anonymous. Rapid diagnostic tests for influenza. Med. Let. Drugs Ther. 41, 121-122 (1999).
9. Ruest A, Michaud S, Deslandes S, Frost EH. Comparison of the Directigen flu A+B test, the QuickVue influenza test, and clinical case definition to viral culture and reverse transcription-PCR for rapid diagnosis of influenza virus infection. J. Clin. Microbiol. 41, 3487-3493 (2003).
10. Uyeki TM. Influenza diagnosis and treatment in children: a review of studies on clinically useful tests and antiviral treatment for influenza. Pediatr. Infect. Dis. J. 22, 164-177 (2003).
11. Rodriguez WJMDP, Schwartz RHM, Thorne MMB. Evaluation of diagnostic tests for influenza in a pediatric practice. Pediatr. Infect. Dis. J. 21, 193-196 (2002).
12. Mostow SR. Prevention, management, and control of influenza. Role of amantadine. Am. J. Med. 82, 35-41 (1987).
13. Jefferson T, Deeks JJ, Demicheli V, Rivetti D, Rudin M. Amantadine and rimantadine for preventing and treating influenza A in adults. Cochrane Database Syst. Rev. 3 (2004).
14. Stange KC, Little DW, Blatnik B. Adverse reactions to amantadine prophylaxis of influenza in a retirement home. J. Am. Geriatr. Soc. 39, 700-705 (1991).
15. Keyser LA, Karl M, Nafziger AN, Bertino JS Jr. Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients. Arch. Intern. Med. 160, 1485-1488 (2000).
16. Dolin R, Reichman RC, Madore HP, Maynard R, Linton PN, Webber-Jones J. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N. Engl. J. Med. 307, 580-584 (1982).
17. Hayden FG, Gwaltney JM Jr, Van de Castle RL, Adams KF, Giordani B. Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adults. Antimicrob. Agents Chemother. 19, 226-233 (1981).
18. Cooper NJ, Sutton AJ, Abrams KR, Wailoo A, Turner D, Nicholson KG. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. Br. Med. J. 326, 1235 (2003).
19. Monto AS, Webster A, Keene O. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. J. Antimicrob. Chemother. 44(Suppl B), 23-29 (1999).
20. Kaiser L, Keene ON, Hammond JM, Elliott M, Hayden FG. Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults. Arch. Intern. Med. 160, 3234-3240 (2000).
21. Nicholson KG, Aoki FY, Osterhaus AD et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 355, 1845-1850 (2000).
22. Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N. Engl. J. Med. 348, 1322-1332 (2003).
23. Nichol KL, Wuorenma J, von Sternberg T. Benefits of influenza vaccination for low-,intermediate-, and high-risk senior citizens. Arch. Intern. Med. 158, 1769-1776 (1998).
24. Nichol KL, Cohen GM, Nettleman MD et al. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine 21, 1769-1775 (2003).
25. Postma MJ, Baltussen RM, Heijnen ML, de Berg LT, Jager JC. Pharmacoeconomics of influenza vaccination in the elderly: reviewing the available evidence. Drugs Aging 17, 217-227 (2000).
26. Davis JW, Lee E, Taira DA, Chung RS. Influenza vaccination, hospitalizations, and costs among members of a Medicare managed care plan. Med. Care 39, 1273-1280 (2001).
27. Nichol KL, Goodman M. The health and economic benefits of influenza vaccination for healthy and at-risk persons aged 65 to 74 years. PharmacoEconomics 16(Suppl. 1), 63-71 (1999).
28. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N. Engl. J. Med. 331, 778-784 (1994).
29. Helliwell BE, Drummond MF. The costs and benefits of preventing influenza in Ontario's elderly. Can. J. Public Health 79, 175-180 (1988).
30. Scuffham PA, West PA. Economic evaluation of strategies for the control and management of influenza in Europe. Vaccine 20, 2562-2578 (2002).
31. Postma MJ, Bos JM, van Gennep M, Jager JC, Baltussen R, Sprenger MJ. Economic evaluation of influenza vaccination. Assessment for The Netherlands. PharmacoEconomics 16(Suppl. 1), 33-40 (1999).
32. Scott WG, Scott HM. Economic evaluation of vaccination against influenza in New Zealand. PharmacoEconomics 9, 51-60 (1996).
33. Wang CS, Wang ST, Chou P. Efficacy and cost-effectiveness of influenza vaccination of the elderly in a densely populated and unvaccinated community. Vaccine 20, 2494-2499 (2002).
34. Ahmed F, Singleton JA, Franks AL. Clinical practice. Influenza vaccination for healthy young adults. N. Engl. J. Med. 345, 1543-1547 (2001).
35. Wood SC, Nguyen VH, Schmidt C. Economic evaluations of influenza vaccination in healthy working-age adults. Employer and society perspective. PharmacoEconomics 18, 173-183 (2000).
36. Demicheli V, Rivetti D, Deeks JJ, Jefferson TO. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst. Rev. CD001269 (2004).
37. Muennig PA, Khan K. Cost-effectiveness of vaccination versus treatment of influenza in healthy adolescents and adults. Clin. Infect. Dis. 33, 1879-1885 (2001).
38. Bridges CB, Thompson WW, Meltzer MI et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA 284, 1655-1663 (2000).
39. Nichol KL. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza. Arch. Intern. Med. 161, 749-759 (2001).
40. Kumpulainen V, Makela M. Influenza vaccination among healthy employees: a cost-benefit analysis. Scand. J. Infect. Dis. 29, 181-185 (1997).
41. Lee PY, Matchar DB, Clements DA, Huber J, Hamilton JD, Peterson ED. Economic analysis of influenza vaccination and antiviral treatment for healthy working adults. Ann. Intern. Med. 137, 225-231 (2002).
42. Rothberg MB, Rose DN. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis. Am. J. Med. 118, 70-79 (2005).
43. Clements DA, Langdon L, Bland C, Walter E. Influenza A vaccine decreases the incidence of otitis media in 6- to 30-month-old children in day care. Arch. Pediatr. Adolesc. Med. 149, 1113-1117 (1995).
44. Heikkinen T, Ruuskanen O, Waris M, Ziegler T, Arola M, Halonen P. Influenza vaccination in the prevention of acute otitis media in children. Am. J. Dis. Child. 145, 445-448 (1991).
45. Luce BR, Zangwill KM, Palmer CS et al. Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children. Pediatrics 108, E24 (2001).
46. Cohen GM, Nettleman MD. Economic impact of influenza vaccination in preschool children. Pediatrics 106, 973-976 (2000).
47. White T, Lavoie S, Nettleman MD. Potential cost savings attributable to influenza vaccination of school-aged children. Pediatrics 103, e73 (1999).
48. Meltzer MI, Neuzil KM, Griffin MR, Fukuda K. An economic analysis of annual influenza vaccination of children. Vaccine 23, 1004-1014 (2005).
49. Turner D, Wailoo A, Nicholson K et al. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol. Assess. 7, 1-170 (2003).
50. Committee on Infectious Diseases. Reduction of the influenza burden in children. Pediatrics 110, 1246-1252 (2002).
51. Belshe RB, Mendelman PM, Treanor J et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N. Engl. J. Med. 338, 1405-1412 (1998).
52. Nichol KL, Mendelman PM, Mallon KP et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 282, 137-144 (1999).
53. Influenza vaccination and self-reported reasons for not receiving influenza vaccination among Medicare beneficiaries aged > or =65 years United States, 1991-2002. MMWR Morb. Mortal Wkly Rep. 53, 1012-105 (2004).
54. Barbaro M. MedImmune to try new FluMist tactic. Washington Post, Washington DC, USA (2004).
55. Friedman MJ, Attia MW. Clinical predictors of influenza in children. Arch. Pediatr. Adolesc. Med. 158, 391-394 (2004).
56. Zambon M, Hays J, Webster A, Newman R, Keene O. Diagnosis of influenza in the community: relationship of clinical diagnosis to confirmed virological, serologic, or molecular detection of influenza. Arch. Intern. Med. 161, 2116-2122 (2001).
57. Blitz SG, Cram P, Chernew ME, Monto AS, Fendrick AM. Diagnostic testing or empirical neuraminidase inhibitor therapy for patients with influenza-like illness: what a difference a day makes. Am. J. Manag. Care 8, 221-227 (2002).
58. Rothberg MB, He S, Rose DN. Management of influenza symptoms in healthy adults. J. Gen. Intern. Med. 18, 808-815 (2003).
59. Rothberg MB, Bellantonio S, Rose DN. Management of influenza in adults older than 65 years of age: cost-effectiveness of rapid testing and antiviral therapy. Ann. Intern. Med. 139, 321-329 (2003).
60. Smith KJ, Roberts MS. Cost-effectiveness of newer treatment strategies for influenza. Am. J. Med. 113, 300-307 (2002).
61. Sintchenko V, Gilbert GL, Coiera E, Dwyer D. Treat or test first? Decision analysis of empirical antiviral treatment of influenza virus infection versus treatment based on rapid test results. J. Clin. Virol. 25, 15-21 (2002).
62. Schwarzinger M, Housset B, Carrat F. Bedside rapid flu test and zanamivir prescription in healthy working adults: a cost-benefit analysis. PharmacoEconomics 21, 215-224 (2003).
63. Hueston WJ, Benich JJ III. A cost-benefit analysis of testing for influenza A in high-risk adults. Ann. Fam. Med. 2, 33-40 (2004).
64. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch. Intern. Med. 163, 1667-1672 (2003).
65. Diggory P, Fernandez C, Humphrey A, Jones V, Murphy M. Comparison of elderly people's technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial. Br. Med. J. 322, 577-579 (2001).
66. Gravenstein S, Davidson HE. Current strategies for management of influenza in the elderly population. Clin. Infect. Dis. 35, 729-737 (2002).
67. Mauskopf JA, Cates SC, Griffin AD, Neighbors DM, Lamb SC, Rutherford C. Cost effectiveness of zanamivir for the treatment of influenza in a high risk population in Australia. PharmacoEconomics 17, 611-620 (2000).
68. Griffin AD, Perry AS, Fleming DM. Cost-effectiveness analysis of inhaled zanamivir in the treatment of influenza A and B in high-risk patients. PharmacoEconomics 19, 293-301 (2001).
69. Armstrong E, Khan Z, Perry A, Hons M, Perri L. The cost effectiveness of zanamivir and oseltamivir for influenza treatment. Formulary 35, 979-989 (2000).
70. Burls A, Clark W, Stewart T et al. Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation. Health Technol. Assess. 6, 1-87 (2002).
71. Husereau D, Brady B, McGeer A. Oseltamivir for the treatment of suspected influenza: a clinical and economic assessment. Canadian Coordinating Office for Health Technology Assessment, Ottowa, Canada (2001).
72. Couch RB, Kasel JA, Glezen WP et al. Influenza: its control in persons and populations. J. Infect. Dis. 153, 431-440 (1986).
73. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflation? Arch. Intern. Med. 163, 1637-1641 (2003).
74. Whitley RJ, Hayden FG, Reisinger KS et al. Oral oseltamivir treatment of influenza in children. Pediatr. Infect. Dis. J. 20, 127-133 (2001).
75. Hedrick JA, Barzilai A, Behre U et al. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr. Infect. Dis. J. 19, 410-417 (2000).
76. Monto AS, Davenport FM, Napier JA, Francis T Jr. Modification of an outbreak of influenza in Tecumseh, Michigan by vaccination of schoolchildren. J. Infect. Dis. 122, 16-25 (1970).
77. Takahashi K, Furuta Y, Fukuda Y et al. In vitro and in vivo activities of T-705 and oseltamivir against influenza virus. Antivir. Chem. Chemother. 14, 235-241 (2003).
78. Tompkins SM, Lo CY, Tumpey TM, Epstein SL. Protection against lethal influenza virus challenge by RNA interference in vivo. Proc. Natl. Acad. Sci. USA 101, 8682-8686 (2004).
79. O'Brien BJ, Goeree R, Blackhouse G, Smieja M. Oseltamivir for treatment of influenza in healthy adults: pooled trial evidence and cost-effectiveness model for Canada. Value Health 6, 116-125 (2003).
80. Brady B, McAuley L, Shukla V. Economic evaluation of zanamivir for the treatment of influenza. Canadian Coordinating Office for Health Technology Assessment, Ottawa, Canada (2001).